Ugandan Biotech Company Files US Patent for Multi-Strain Ebola mRNA Vaccine Platform
Key Insights
Dei BioPharma (search) has filed a US patent application for an innovative mRNA vaccine designed to protect against multiple Ebola (search) virus strains, including Zaire, Sudan, and Bundibugyo viruses.
The vaccine platform addresses a critical gap in current Ebola (search) preparedness, as existing approved vaccines like ERVEBO only protect against Zaire ebolavirus (search), leaving no licensed protection against other outbreak-causing strains.
The company plans to begin Phase One human trials and pursue conditional approval within four to five years, with manufacturing capacity targeting 5-10 million doses annually at their Matugga facility near Kampala.
Ugandan pharmaceutical company Dei BioPharma (search) has filed a utility patent application with the United States Patent and Trademark Office for a next-generation mRNA vaccine platform designed to provide protection against multiple strains of the Ebola (search) virus. The filing represents a significant advancement in addressing critical gaps in current Ebola preparedness, particularly for African nations where these viruses pose the greatest threat.
Addressing Multi-Strain Protection Gap
The patent application covers an mRNA vaccine that targets the main Ebola (search) viruses linked to past epidemics, including Zaire Ebolavirus (search), which caused the devastating 2014-2016 West Africa outbreak, Sudan Ebolavirus (search), and Bundibugyo Ebolavirus (search). This multi-strain approach represents a departure from existing vaccines that provide protection against only single virus strains.
Currently, the only approved Ebola (search) vaccine, ERVEBO, is licensed exclusively for Zaire ebolavirus (search) protection. The World Health Organization has confirmed that no licensed vaccine or specific treatment exists for Bundibugyo virus disease, a gap that has become increasingly urgent following WHO's recent declaration of the current Bundibugyo virus disease outbreak in Uganda and the Democratic Republic of Congo as a Public Health Emergency of International Concern.
Dr. Matthias Magoola, founder of Dei BioPharma (search), explained the innovative approach: "For decades, ebolavirus preparedness has been approached as a challenge requiring separate vaccines for separate viral threats. Our innovation challenges that paradigm by using rational antigen engineering to pursue broad protection against the most consequential outbreak-causing Ebolaviruses."
Technical Innovation and Design
The vaccine utilizes mRNA technology delivered through lipid nanoparticles, the same carrier technology used in modern mRNA vaccines. The company employs two distinct design approaches to achieve broad protection. One method identifies genetic features common across different Ebola (search) viruses, while the other combines selected natural genetic segments from different strains to widen protection while maintaining the structural integrity of the virus proteins.
The patent filing contains 24 claims covering vaccine design, mRNA delivery systems, lipid nanoparticle formulations, manufacturing processes, dosage schedules, and potential use during outbreaks, including protection of frontline health workers and people at high risk of exposure.
Clinical Development Timeline
Dei BioPharma (search) is preparing for Phase One human clinical trials and pursuing a regulatory pathway that could allow conditional approval within four to five years from the start of development. Under the company's current five-year development plan, they intend to submit an Investigational New Drug application to the US Food and Drug Administration (search) before beginning Phase One trials in healthy volunteers, focusing on safety, side effects, and determining optimal dosage.
Phase Two trials are expected to involve larger and more diverse participant groups, while Phase Three studies would assess immune responses and vaccine effectiveness. The company plans to seek accelerated regulatory review if clinical results prove favorable.
Manufacturing and Distribution Strategy
To prepare for future deployment, Dei BioPharma (search) is engaging manufacturing partners for both clinical and commercial production. The company estimates that annual production capacity could reach between five million and ten million doses after approval, utilizing their manufacturing facility in Matugga, near Kampala.
The vaccine formulation is designed for practical deployment, remaining stable for up to 24 months at minus 20 degrees Celsius and between six and 12 months when stored at standard refrigerator temperatures of 2 to 8 degrees Celsius.
Strategic Partnerships and Global Health Impact
Dei BioPharma (search) is actively discussing future procurement, stockpiling, and distribution arrangements with major international and regional health organizations, including the World Health Organization, the Coalition for Epidemic Preparedness Innovations (search) (CEPI), Gavi (search), the Vaccine Alliance, and ministries of health across Africa.
The 2014-2016 outbreak in Guinea, Liberia, and Sierra Leone remains the largest Ebola (search) outbreak on record, with more than 28,600 reported cases and 11,325 deaths according to WHO data. Most major Ebola outbreaks have occurred in sub-Saharan Africa, where contact between humans and infected wildlife can trigger new infections.
Dr. Magoola emphasized the broader implications of the development: "This is not only a scientific milestone. It is a step toward African technological self-determination in epidemic preparedness. Africa must not only receive vaccines during crises; Africa must help design, manufacture and deploy them."
The company has committed to adopting equitable pricing during outbreaks and plans to use its regional manufacturing capacity to strengthen vaccine supply chains across Africa, potentially reducing response times and dependence on international suppliers during future health emergencies.